Octave Bioscience
Hemali Patel has worked in the clinical laboratory field since 2002. Hemali began their career at Beckman Coulter as a Clinical Application Specialist in 2002. In 2007, they moved to Ascend Clinical as an Immunochemistry Manager. From 2014 to 2019, they worked at Crescendo Bioscience, holding the roles of Group Manager, Technical Supervisor, and General Supervisor. In 2019, they joined Octave as a Director - Clinical Laboratory and was later promoted to Associate Director - Clinical Laboratory.
Hemali Patel attended The University of Tennessee Health Science Center.
This person is not in any offices
Octave Bioscience
Octave Bioscience’s Comprehensive Care Platform provides a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. It provides multiple layers of insight to provide a 360 degree view with a longitudinal perspective of disease progression. The first layer measures the patient’s underlying biology with blood based biomarkers that quantitatively and objectively assess inflammation and immune modulation. The second layer includes advanced measurement using improved MRI readings and interpretation to reveal more insights at the CNS layer, including the brain and spine. The final layer features real time tracking of symptoms via monitoring with mobile tools, sensors and wearables to identify changes in disease and alert care teams. All of this data is integrated into protocols, supported by decision support tools and feeds into a dashboard for ease of use. The Octave Platform allows individual and population views to facilitate better stratification and contextual interventions.